Profile data is unavailable for this security.
About the company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
- Revenue in CHF (TTM)6.53bn
- Net income in CHF909.00m
- Incorporated2002
- Employees19.77k
- LocationLonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
- Phone+41 613168111
- Fax+41 613169111
- Websitehttps://www.lonza.com/
Mergers & acquisitions
| Acquired company | LONN:SWX since announced | Transaction value |
|---|---|---|
| Redberry Sas | -11.66% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qiagen NV | 1.63bn | 331.13m | 7.83bn | 5.65k | 24.44 | 2.80 | 16.25 | 4.81 | 1.71 | 1.71 | 8.39 | 14.93 | 0.3488 | 2.66 | 5.45 | 316,290.70 | 7.09 | 5.89 | 7.77 | 6.96 | 62.97 | 63.60 | 20.33 | 17.13 | 3.31 | -- | 0.3045 | -- | 5.65 | 2.25 | 408.28 | 3.42 | -7.40 | -- |
| Eurofins Scientific SE | 6.15bn | 603.15m | 11.27bn | 65.69k | 19.13 | 2.64 | 9.13 | 1.83 | 3.55 | 2.20 | 36.23 | 25.71 | 0.6177 | 36.38 | 4.79 | 102,842.00 | 6.63 | 7.27 | 8.41 | 9.08 | 24.29 | 23.69 | 10.74 | 11.01 | 1.03 | 8.55 | 0.492 | 23.70 | -2.80 | 4.43 | 4.37 | -0.2934 | 8.58 | 1.15 |
| Genmab A/S | 2.90bn | 750.29m | 14.78bn | 3.03k | 19.15 | 3.11 | 18.35 | 5.10 | 98.55 | 98.55 | 378.67 | 606.39 | 0.3858 | 17.63 | 3.66 | 7,848,353.00 | 9.99 | 14.22 | 11.25 | 15.57 | 93.60 | 96.72 | 25.89 | 31.44 | 2.01 | -- | 0.4813 | -- | 19.19 | 19.19 | -15.00 | 5.77 | 3.22 | -- |
| argenx SE | 3.24bn | 1.01bn | 37.00bn | 1.60k | 39.30 | -- | -- | 11.43 | 16.70 | 16.70 | 53.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 89.15 | -- | 31.12 | 8.40 | -- | -- | -- | -- | 89.54 | 151.52 | 55.10 | -- | -- | -- |
| Lonza Group AG | 6.53bn | 909.00m | 37.24bn | 19.77k | 40.97 | 3.98 | 23.93 | 5.70 | 12.94 | 13.51 | 93.02 | 133.07 | 0.3375 | 2.45 | 4.32 | 330,332.30 | 4.70 | 4.70 | 5.78 | 5.72 | 36.15 | 37.28 | 13.92 | 13.02 | 1.77 | 7.77 | 0.313 | 34.17 | -0.6541 | 7.70 | 42.92 | 4.48 | 7.13 | 10.76 |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 03 Feb 2026 | 3.20m | 4.56% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.59m | 3.68% |
| Norges Bank Investment Managementas of 04 Feb 2026 | 2.10m | 2.99% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 1.31m | 1.86% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jan 2026 | 1.20m | 1.71% |
| BlackRock Investment Management (UK) Ltd.as of 27 Feb 2026 | 919.93k | 1.31% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 893.63k | 1.27% |
| Invesco Advisers, Inc.as of 06 Feb 2026 | 808.31k | 1.15% |
| Geode Capital Management LLCas of 26 Feb 2026 | 792.15k | 1.13% |
| Schroder Investment Management Ltd.as of 31 Jan 2026 | 694.32k | 0.99% |
